Identification
- Summary
Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine is a conjugate vaccine used to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135.
- Brand Names
- Menveo
- Generic Name
- Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine
- DrugBank Accession Number
- DB10061
- Background
Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine is used to prevent invasive meningococcal disease, which is caused by bacteria Neisseria meningitidis entering the bloodstream and invading the blood-brain barrier to cause a variety of infections such as septicemia, meningitis, and pneumonia.1 Several serogroups of N. meningitidis - A, B, C, Y, and W-135 - known to cause meningococcal infections have been identified.1 Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine contains serogroup A, C, Y, and W-135 oligosaccharides conjugated individually to Corynebacterium diphtheriae CRM197 protein carrier, resulting in four drug substances contained in each dose of vaccine.2
Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, marketed as MENVEO, was first approved by the FDA in 2010.2
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Vaccines
Other vaccines - Synonyms
- Not Available
Pharmacology
- Indication
This is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 2 months through 55 years of age. Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine does not prevent N. meningitidis serogroup B infections.2
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Prevention of Invasive meningococcal disease caused by neisseria meningitidis serogroup c •••••••••••• Prevention of Invasive meningococcal infection caused by neisseria meningitidis serogroup a •••••••••••• Prevention of Invasive meningococcal infection caused by neisseria meningitidis serogroup w-135 •••••••••••• Prevention of Invasive meningococcal infection caused by neisseria meningitidis serogroup y •••••••••••• - Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine that works to potentiate immune response against Neisseria meningitidis serogroups A, C, Y, and W-135 in vaccinated individuals.2
- Mechanism of action
Neisseria meningitidis is a human-encapsulated Gram-negative diplococcus that is known to cause serious and life-threatening invasive disease. N. meningitidis has several different serogroups that are classified based on the composition of capsular polysaccharide (CPS) polymers. Among the serogroups, serogroups A, B, C, W, Y, and X account for the majority of meningococcal diseases.1
Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine contains bacterial CPS (serogroup A, C, Y, and W-135 oligosaccharides) conjugated to a carrier protein (CRM197), allowing more robust antibody responses compared to plain polysaccharide vaccines.1 Upon administration, this conjugate vaccine promotes the production of bactericidal antibodies directed against the capsular polysaccharides of serogroups A, C, Y, and W-135 in vaccinated individuals.2
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Abatacept. Adalimumab The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Adalimumab. Alclometasone The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Alclometasone. Aldesleukin The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Aldesleukin. Alefacept The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Alefacept. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Menjugate Liquid Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine (25 mcg/0.5mL) + Meningococcal polysaccharide vaccine group C (10 mcg/0.5mL) Suspension Intramuscular Glaxosmithkline Inc 2015-10-07 Not applicable Canada 
Menveo Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine (3.3-33.3 mcg/0.5mL) + Meningococcal polysaccharide vaccine group A (10 mcg/0.5mL) + Meningococcal polysaccharide vaccine group C (5 mcg/0.5mL) + Meningococcal polysaccharide vaccine group W-135 (5 mcg/0.5mL) + Meningococcal polysaccharide vaccine group Y (5 mcg/0.5mL) Powder, for solution; Solution Intramuscular Glaxosmithkline Inc 2010-07-29 Not applicable Canada
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Neisseria meningitidis
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
References
- General References
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Active Not Recruiting Prevention Papilloma Viral Infection 1 4 Completed Basic Science Meningitis / Meningococcal Disease / Septicemia 1 4 Completed Other Meningococcal Meningitis 1 4 Completed Prevention Invasive Meningococcal Disease 1 4 Completed Prevention Meningococcal Disease 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Suspension Intramuscular Powder, for solution; solution Intramuscular - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at November 30, 2015 21:23 / Updated at November 01, 2022 19:17